Patrick Gyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Patrick Gyan has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Cedric Dzidzor Kodjo Amengor
Department of Pharmaceutical Chemistry, Drug Discovery Unit, School of Pharmacy, University of Health and Allied Sciences, Ho, Ghana
3 shared publications - Abena Amponsaa Brobbey
Kwame Nkrumah University of Science and Technology
1 shared publication Benedicta Yayra Adzah
Department of Pharmaceutical Chemistry, Drug Discovery Unit, School of Pharmacy, University of Health and Allied Sciences, Ho, Ghana
1 shared publication- Benjamin Kingsley Harley
Affiliation Department of Pharmacognosy and Herbal Medicine, School of Pharmacy, University of Health and Allied Sciences, Ho, Ghana
1 shared publication - Billy Mawunyo Abudey
Department of Pharmaceutical Chemistry School of Pharmacy University of Health and Allied Sciences Ho Ghana uhas.edu.gh
1 shared publication - Cynthia Amaning Danquah
Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology, PMB, Kumasi, Ghana
1 shared publication
Latest Publications
- Open Access
- 11 February 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (10) , 8921-8944
Dual-targeting sulfamethoxazole derivatives overcome multidrug resistance in ESKAPE pathogens by inhibiting quorum sensing and efflux pumps
The rapid emergence of pan-drug-resistant pathogens necessitates innovative antimicrobial strategies that overcome conventional resistance. This study reports the structure-guided design of sulfamethoxazole derivatives as dual inhibitors of quorum sensing (LasR) and efflux pumps (AcrB), alongside the classic dihydropteroate synthase (DHPS) target. High-throughput virtual screening of 54 derivatives, followed by MM-GBSA analysis, prioritized five novel compounds for synthesis. Their structures were confirmed by 1H/13C NMR, FT-IR, and mass spectrometry. All compounds demonstrated potent growth inhibition (MICs 15.625–125 µg mL−1) against Proteus mirabilis, Salmonella typhi, and Escherichia coli, though activity against the more resistant Pseudomonas aeruginosa was reduced. Critically, lead compounds SMX033 and SMX015 achieved >99% biofilm inhibition against P. mirabilis, and SMX033 showed significant efflux pump inhibition, directly validating our in silico predictions of a multi-target mechanism. In particular, compound SMX033 exhibited the best antimicrobial activity and lowest cytotoxicity of all the sulfamethoxazole derivatives with a CCC50 value of 286.20 µM against Vero cells. Despite their predicted in silico genotoxicity, these derivatives provide promising chemical scaffolds for combating multidrug-resistant infections by concurrently attenuating virulence and restoring antibiotic susceptibility.
- 11 February 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (10) , 8921-8944
Open AccessDual-targeting sulfamethoxazole derivatives overcome multidrug resistance in ESKAPE pathogens by inhibiting quorum sensing and efflux pumps
The rapid emergence of pan-drug-resistant pathogens necessitates innovative antimicrobial strategies that overcome conventional resistance. This study reports the structure-guided design of sulfamethoxazole derivatives as dual inhibitors of quorum sensing (LasR) and efflux pumps (AcrB), alongside the classic dihydropteroate synthase (DHPS) target. High-throughput virtual screening of 54 derivatives, followed by MM-GBSA analysis, prioritized five novel compounds for synthesis. Their structures were confirmed by 1H/13C NMR, FT-IR, and mass spectrometry. All compounds demonstrated potent growth inhibition (MICs 15.625–125 µg mL−1) against Proteus mirabilis, Salmonella typhi, and Escherichia coli, though activity against the more resistant Pseudomonas aeruginosa was reduced. Critically, lead compounds SMX033 and SMX015 achieved >99% biofilm inhibition against P. mirabilis, and SMX033 showed significant efflux pump inhibition, directly validating our in silico predictions of a multi-target mechanism. In particular, compound SMX033 exhibited the best antimicrobial activity and lowest cytotoxicity of all the sulfamethoxazole derivatives with a CCC50 value of 286.20 µM against Vero cells. Despite their predicted in silico genotoxicity, these derivatives provide promising chemical scaffolds for combating multidrug-resistant infections by concurrently attenuating virulence and restoring antibiotic susceptibility.
- Open Access
- 13 February 2024
- Published by Wiley in BioMed Research International
- Vol. 2024, 1-13
N-Substituted Phenylhydrazones Kill the Ring Stage of Plasmodium falciparum
Antimalarial resistance has hampered the effective treatment of malaria, a parasitic disease caused by Plasmodium species. As part of our campaign on phenotypic screening of phenylhydrazones, a library of six phenylhydrazones was reconstructed and evaluated for their in vitro antimalarial and in silico receptor binding and pharmacokinetic properties. The structures of the phenylhydrazone hybrids were largely confirmed using nuclear magnetic resonance techniques. We identified two compounds which exhibited significant antimalarial potential against the ring stage (trophozoite) of 3D7 chloroquine-sensitive (CS) strain and DD2 chloroquine-resistant (CR) strains of Plasmodium falciparum with monosubstituted analogs bearing meta or para electron-donating groups showing significant activity in the single-digit micromolar range. Structure activity relationship is presented showing that electron-donating groups on the substituent hydrophobic pharmacophore are required for antimalarial activity. Compounds PHN6 and PHN3 were found to be the most potent with pIC50s (calculated form in vitro IC50s) of 5.37 and 5.18 against 3D7 CS and DD2 CR strains, respectively. Our selected ligands (PHN3 and PHN6) performed better when compared to chloroquine regarding binding affinity and molecular stability with the regulatory proteins of Plasmodium falciparum, hence predicted to be largely responsible for their in vitro activity. Pharmacokinetic prediction demonstrated that the phenylhydrazones may not cross the blood-brain barrier and are not P-glycoprotein (P-gp) substrates, a good absorption of 62 to 69, and classified as a category IV compound based on toxicity grading.
- 13 February 2024
- Published by Wiley in BioMed Research International
- Vol. 2024, 1-13
Open AccessN-Substituted Phenylhydrazones Kill the Ring Stage of Plasmodium falciparum
Antimalarial resistance has hampered the effective treatment of malaria, a parasitic disease caused by Plasmodium species. As part of our campaign on phenotypic screening of phenylhydrazones, a library of six phenylhydrazones was reconstructed and evaluated for their in vitro antimalarial and in silico receptor binding and pharmacokinetic properties. The structures of the phenylhydrazone hybrids were largely confirmed using nuclear magnetic resonance techniques. We identified two compounds which exhibited significant antimalarial potential against the ring stage (trophozoite) of 3D7 chloroquine-sensitive (CS) strain and DD2 chloroquine-resistant (CR) strains of Plasmodium falciparum with monosubstituted analogs bearing meta or para electron-donating groups showing significant activity in the single-digit micromolar range. Structure activity relationship is presented showing that electron-donating groups on the substituent hydrophobic pharmacophore are required for antimalarial activity. Compounds PHN6 and PHN3 were found to be the most potent with pIC50s (calculated form in vitro IC50s) of 5.37 and 5.18 against 3D7 CS and DD2 CR strains, respectively. Our selected ligands (PHN3 and PHN6) performed better when compared to chloroquine regarding binding affinity and molecular stability with the regulatory proteins of Plasmodium falciparum, hence predicted to be largely responsible for their in vitro activity. Pharmacokinetic prediction demonstrated that the phenylhydrazones may not cross the blood-brain barrier and are not P-glycoprotein (P-gp) substrates, a good absorption of 62 to 69, and classified as a category IV compound based on toxicity grading.
- Open Access
- 18 June 2022
- Published by Sciencedomain International in Journal of Pharmaceutical Research International
- p. 68-80
Antimicrobial Activity and In silico ADME Prediction of Synthesised 8-hydroxyquinoline Azo Compounds against Some ESKAPE Human Pathogens and Mycobacterium smegmatis
Introduction: Antimicrobial resistance has increasingly been a global health concern over the past decades and that has necessitated the quest to increase the pool of antibiotics. Methods: Five (5) azo compounds were synthesised by diazotization and coupling procedures with yields of 60 – 92%. They were characterized by melting point determination, Ultra-Violet Visible, and Infra-red spectroscopy. High-throughput spot culture growth inhibition (HT-SPOTi) antimicrobial assay was used to evaluate the compounds. Computational studies was also employed to predict some pharmacokinetic properties of the azo compounds Results: From the in silico studies, none of the compounds violated Lipinski’s rule and therefore, have the potential to be developed into an oral drug. They also showed Total Polar Surface Area (TPSA) values < 140 A2 (74.91 – 100.98 A2) and percentage absorption of 74 – 83 %. They were placed in category III of acute oral drugs. From the high-throughput spot culture growth inhibition antimicrobial assay, all the compounds possessed inhibitory activity against the ESKAPE human pathogens and Mycobacterium smegmatis, with MICs range of 3.9 \(\geq\) 500 \(\mu g/mL\). Except for 4e which showed liver toxicity, all the compounds demonstrated mutagenic and hepatotoxic tendencies. The modulatory assay of the azo compounds revealed that 4c and 4e modulated the antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus. 4c and 4e also modulated the antimicrobial activity of rifampicin against Mycobacterium smegmatis. Exploiting the ability of 4c and 4e to act by a mode of action revealed that they have biofilm formation inhibitory potential. Conclusion: Compounds 4c and 4e exhibited the best antimicrobial activity in terms of resistant modulation and biofilm inhibition against Pseudomonas aeruginosa, Staphylococcus aureus and Mycobacterium smegmatis.- 18 June 2022
- Published by Sciencedomain International in Journal of Pharmaceutical Research International
- p. 68-80
Open AccessAntimicrobial Activity and In silico ADME Prediction of Synthesised 8-hydroxyquinoline Azo Compounds against Some ESKAPE Human Pathogens and Mycobacterium smegmatis
Introduction: Antimicrobial resistance has increasingly been a global health concern over the past decades and that has necessitated the quest to increase the pool of antibiotics. Methods: Five (5) azo compounds were synthesised by diazotization and coupling procedures with yields of 60 – 92%. They were characterized by melting point determination, Ultra-Violet Visible, and Infra-red spectroscopy. High-throughput spot culture growth inhibition (HT-SPOTi) antimicrobial assay was used to evaluate the compounds. Computational studies was also employed to predict some pharmacokinetic properties of the azo compounds Results: From the in silico studies, none of the compounds violated Lipinski’s rule and therefore, have the potential to be developed into an oral drug. They also showed Total Polar Surface Area (TPSA) values < 140 A2 (74.91 – 100.98 A2) and percentage absorption of 74 – 83 %. They were placed in category III of acute oral drugs. From the high-throughput spot culture growth inhibition antimicrobial assay, all the compounds possessed inhibitory activity against the ESKAPE human pathogens and Mycobacterium smegmatis, with MICs range of 3.9 \(\geq\) 500 \(\mu g/mL\). Except for 4e which showed liver toxicity, all the compounds demonstrated mutagenic and hepatotoxic tendencies. The modulatory assay of the azo compounds revealed that 4c and 4e modulated the antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus. 4c and 4e also modulated the antimicrobial activity of rifampicin against Mycobacterium smegmatis. Exploiting the ability of 4c and 4e to act by a mode of action revealed that they have biofilm formation inhibitory potential. Conclusion: Compounds 4c and 4e exhibited the best antimicrobial activity in terms of resistant modulation and biofilm inhibition against Pseudomonas aeruginosa, Staphylococcus aureus and Mycobacterium smegmatis.